Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Have there been any head-to-head comparisons between Tarceva and chemotherapy in NSCLC?

April 26, 2017chemotherapy comparisons head-to-head nsclc Tarceva

0

Posted

Have there been any head-to-head comparisons between Tarceva and chemotherapy in NSCLC?

1 Answer

0

Posted

There have been no head-to-head studies comparing Tarceva and chemotherapy. In the SATURN trial for NSCLC maintenance therapy, Tarceva monotherapy 150 mg was compared with placebo in stage IIIB/IV NSCLC patients. In the BR.21 trial for relapsed or refractory NSCLC, Tarceva monotherapy 150 mg was compared with placebo in stage IIIB/IV NSCLC patients.